NeoGenomics (NEO) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

NeoGenomics

NasdaqCM•Healthcare•Diagnostics & Research

$18.94+0.05(<0.01%)Pre-market

Market Cap

$2.58B

P/S

3.4x

P/B

3.3x

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

How this company scores

WeakMetricSide Score: 53/100

Grade capped at D — Interest coverage below 1× (-21.9x) — earnings cannot cover interest. Strongest: Growth (19/25); weakest: Cash & Earnings Quality (7/25).

Profitability17/25

Growth19/25

Balance Sheet & Red Flags10/25

Cash & Earnings Quality7/25

Strengths

Long cash runwayLow leverageProfit converts from growthConsistent growth

Grade capped at D

Interest coverage below 1× (-21.9x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 122.5x5y range 122.5x – 122.5x

P/S · 3.4x5y range 1.2x – 12.3x

Currently near its 20-quarter median.

P/B · 3.3x5y range 1.0x – 5.3x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 5 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $2.58B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $766.29M
Q. Revenue: $201.66M
TTM EBITDA: $-2.98M
TTM Op. Income: $-68.44M
Q. Op. Income: $-9.77M
TTM Net Income: $-51.88M
Q. Net Income: $2.24M
EPS: $0.02
Shares Out.: $129.63M

$766.29M in TTM revenue grew 11.2% YoY, reaching $201.66M last quarter. TTM EBITDA of $-2.98M and TTM operating income of $-68.44M show growth is flowing through to the bottom line. However, net income is negative at $51.88M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 45.6%
EBITDA Margin: 3.2%
Op. Margin: -4.8%
Net Margin: 1.1%

Op. margin of -4.8% is up 21.4% YoY — cost efficiency is improving. Net margin at 1.1% and gross margin of 45.6% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 82% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 3.4x
P/B Ratio: 3.3x

P/S of 3.4x and P/B of 3.3x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.35B
Cash: $145.54M
Long-Term Debt: $374.24M
Book Value: $785.73M
D/E Ratio: 0.5
Debt/EBITDA: 58.1

With $1.35B in assets and $374.24M in long-term debt, D/E is 0.5and book value is $785.73M — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has risen for 7 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $19.96M
TTM Free Cash Flow: $-7.36M
FCF Margin: -1.0%
FCF / Net Income: 0.1

TTM FCF of $-7.36M on $19.96M in operating cash flow. The FCF / Net Income ratio of 0.1x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is up 62% — a weakening trend.